Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5877573 | Cor et Vasa | 2013 | 6 Pages |
Abstract
Aspirin reduces vascular death by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful. The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Barbora Nussbaumerová, Hana Rosolová,